Oncologie, Inc., aims to advance the state of the art of precision medicine to dramatically improve the lives of people with cancer. Leveraging a deep understanding of the evolving biology of cancer, Oncologie is developing unique RNA-based biomarker panels to match patients to novel, targeted therapies that modulate the bodyᅢᄁ¬ツᆲ¬トᄁs tumor immune system and angiogenesis pathways. Oncologieᅢᄁ¬ツᆲ¬トᄁs Bavituximab is an investigational chimeric monoclonal antibody that targets the activity of phosphatidylserine and is in development for patients with gastric cancer. Oncologieᅢᄁ¬ツᆲ¬トᄁs. Navicixizumab is a bi-specific antibody targeting Delta-like ligand 4 (DLL4) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (VEGF) in development for patients with ovarian cancer and other solid tumors. Oncologie, Inc., based in Waltham, Massachusetts, and Oncologie Shanghai Co., Ltd., based in Shanghai, China, are subsidiaries of Oncologie, Ltd., and are working with global partners to acquire and further develop innovative drugs for cancer patients around the world.